Intrapleural administration of a serotype 5 adeno-associated virus coding for α1-antitrypsin mediates persistent, high lung and serum levels of α1-antitrypsin

Molecular Therapy

Volumn 10, Issue 6, 2004, Pages 1003-1010

  De, Bishnu ^a   Heguy, Adriana ^a   Leopold, Philip L ^a   Wasif, Nabil ^a   Korst, Robert J ^a   Hackett, Neil R ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ANTITRYPSIN; PARVOVIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIAPHRAGM; DRUG BLOOD LEVEL; GENE EXPRESSION; GENE THERAPY; GENETIC CODE; HEART; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; LUNG; MOUSE; MOUSE STRAIN; NONHUMAN; REPORTER GENE; RISK ASSESSMENT; SEROTYPE; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS TYPING;

ALPHA 1-ANTITRYPSIN; ANIMALS; CELL LINE; DEPENDOVIRUS; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; HUMANS; LUNG; MICE; MICE, INBRED C57BL; PLEURA; SERUM; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ANIMALIA;

EID: 10344235189     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.08.022     Document Type: Article

References (64)

1. J.E. Gadek R.G. Crystal a1-Antitrypsin deficiency In: J. Stanbury J. Wyngaarden D.S. Fredrickson J.L. Goldstein M.S. Brown (Eds.) Metabolic Basis of Inherited Disease 1982 McGraw-Hill New York 1450-1467
2. J. Travis G.S. Salvesen Human plasma proteinase inhibitors Annu. Rev. Biochem. 52 1983 655-709
3. M. Brantly T. Nukiwa R.G. Crystal Molecular basis of alpha-1-antitrypsin deficiency Am. J. Med. 84 1988 13-31
4. R.G. Crystal M.L. Brantly R.C. Hubbard D.T. Curiel D.J. States M.D. Holmes The alpha 1-antitrypsin gene and its mutations: Clinical consequences and strategies for therapy Chest 95 1989 196-208
5. R.G. Crystal Alpha 1-antitrypsin deficiency, emphysema, and liver disease: Genetic basis and strategies for therapy J. Clin. Invest. 85 1990 1343-1352
6. R.W. Carrell D.A. Lomas Alpha1-antitrypsin deficiency - a model for conformational diseases N. Engl. J. Med. 346 2002 45-53
7. D.A. Lomas R. Mahadeva Alpha1-antitrypsin polymerization and the serpinopathies: Pathobiology and prospects for therapy J. Clin. Invest. 110 2002 1585-1590
8. M.D. Wewers M.A. Casolaro R.G. Crystal Comparison of alpha-1-antitrypsin levels and antineutrophil elastase capacity of blood and lung in a patient with the alpha-1-antitrypsin phenotype null-null before and during alpha-1-antitrypsin augmentation therapy Am. Rev. Respir. Dis. 135 1987 539-543
9. M.D. Wewers et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema N. Engl. J. Med 316 1987 1055-1062
10. R.C. Hubbard R.G. Crystal Alpha-1-antitrypsin augmentation therapy for alpha-1-antitrypsin deficiency Am. J. Med. 84 1988 52-62
11. R.C. Hubbard R.G. Crystal Augmentation therapy of alpha 1-antitrypsin deficiency Eur. Respir. J. Suppl. 9 1990 44s-52s
12. T.R. Flotte Recombinant adeno-associated virus gene therapy for cystic fibrosis and alpha(1)-antitrypsin deficiency Chest 121 2002 98S-102S
13. G.P. Gao M.R. Alvira L. Wang R. Calcedo J. Johnston J.M. Wilson Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy Proc. Natl. Acad. Sci. USA 99 2002 11854-11859
14. S. Song et al. Sustained secretion of human alpha-1-antitrypsin from murine muscle transduced with adeno-associated virus vectors Proc. Natl. Acad. Sci. USA 95 1998 14384-14388
15. S. Song J. Embury P.J. Laipis K.I. Berns J.M. Crawford T.R. Flotte Stable therapeutic serum levels of human alpha-1 antitrypsin (AAT) after portal vein injection of recombinant adeno-associated virus (rAAV) vectors Gene Ther. 8 2001 1299-1306
16. S. Song P.J. Laipis K.I. Berns T.R. Flotte Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle Proc. Natl. Acad. Sci. USA 98 2001 4084-4088
17. S. Song et al. Intramuscular administration of recombinant adeno-associated virus 2 alpha-1 antitrypsin (rAAV-SERPINA1) vectors in a nonhuman primate model: Safety and immunologic aspects Mol. Ther. 6 2002 329-335
18. C.S. Manno et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood 101 2003 2963-2972
19. T.R. Flotte et al. Phase I trial of intramuscular injection of a recombinant adenoassociated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults Hum. Gene Ther. 15 2004 93-128
20. K. High et al. Immune responses to AAV and to factor IX in a Phase I study of AAV-mediated, liver-directed gene transfer for hemophilia B Mol. Ther. 9 2004 S383
21. R.W. Light Pleural Disease 2001 Lippincott Williams & Wilkins Philadelphia
22. M. Mae R.G. Crystal Gene transfer to the pleural mesothelium as a strategy to deliver proteins to the lung parenchyma Hum. Gene Ther. 13 2002 1471-1482
23. K.R. Clark F. Voulgaropoulou D.M. Fraley P.R. Johnson Cell lines for the production of recombinant adeno-associated virus Hum. Gene Ther. 6 1995 1329-1341
24. D. Grimm A. Kern K. Rittner J.A. Kleinschmidt Novel tools for production and purification of recombinant adenoassociated virus vectors Hum. Gene Ther. 9 1998 2745-2760
25. J. Qiu B.S. Mendez R.G. Crystal N.R. Hackett Construction and verification of an Ad/AAV helper plasmid designed for manufacturing recombinant AAV vector for human administration Mol. Ther. 5 2002 S47
26. D. Grimm Production methods for gene transfer vectors based on adeno-associated virus serotypes Methods 28 2002 146-157
27. J.E. Rabinowitz et al. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity J. Virol. 76 2002 791-801
28. W.W. Hauswirth A.S. Lewin S. Zolotukhin N. Muzyczka Production and purification of recombinant adeno-associated virus Methods Enzymol. 316 2000 743-761
29. S. Zolotukhin et al. Recombinant adeno-associated virus purification using methods improves infectious titer and yield Gene Ther. 6 1999 973-985
30. S. Worgall et al. Selective expansion of alveolar macrophages in vivo by adenovirus-mediated transfer of the murine granulocyte-macrophage colony-stimulating factor cDNA Blood 93 1999 655-666
31. M.L. Brantly J.T. Wittes C.F. Vogelmeier R.C. Hubbard G.A. Fells R.G. Crystal Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes Chest 100 1991 703-708
32. R.I. Garver et al. Production of glycosylated physiologically "normal" human alpha 1-antitrypsin by mouse fibroblasts modified by insertion of a human alpha 1-antitrypsin cDNA using a retroviral vector Proc. Natl. Acad. Sci. USA 84 1987 1050-1054
33. M.A. Rosenfeld et al. Adenovirus-mediated transfer of a recombinant alpha 1-antitrypsin gene to the lung epithelium in vivo Science 252 1991 431-434
34. H.A. Jaffe et al. Adenovirus-mediated in vivo gene transfer and expression in normal rat liver Nat. Genet. 1 1992 372-378
35. M.A. Kay F. Graham F. Leland S.L. Woo Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes Hepatology 21 1995 815-819
36. Y. Setoguchi H.A. Jaffe C.S. Chu R.G. Crystal Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation Am. J. Respir. Cell Mol. Biol. 10 1994 369-377
37. N. Morral et al. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons Proc. Natl. Acad. Sci. USA 96 1999 12816-12821
38. G. Schiedner et al. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity Nat. Genet. 18 1998 180-183
39. A.E. Canonico J.D. Plitman J.T. Conary B.O. Meyrick K.L. Brigham No lung toxicity after repeated aerosol or intravenous delivery of plasmid-cationic liposome complexes J. Appl. Physiol. 77 1994 415-419
40. A.E. Canonico J.T. Conary B.O. Meyrick K.L. Brigham Aerosol and intravenous transfection of human alpha 1-antitrypsin gene to lungs of rabbits Am. J. Respir. Cell Mol. Biol. 10 1994 24-29
41. K.L. Brigham et al. Transfection of nasal mucosa with a normal alpha1-antitrypsin gene in alpha1-antitrypsin-deficient subjects: comparison with protein therapy Hum. Gene Ther. 11 2000 1023-1032
42. B.L. Davidson et al. Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system Proc. Natl. Acad. Sci. USA 97 2000 3428-3432
43. C.L. Halbert E.A. Rutledge J.M. Allen D.W. Russell A.D. Miller Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes J. Virol. 74 2000 1524-1532
44. J. Zabner et al. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer J. Virol. 74 2000 3852-3858
45. D. Duan Z. Yan Y. Yue W. Ding J.F. Engelhardt Enhancement of muscle gene delivery with pseudotyped adeno-associated virus type 5 correlates with myoblast differentiation J. Virol. 75 2001 7662-7671
46. C.L. Halbert J.M. Allen A.D. Miller Adeno-associated virus type 6 (AAV6) vectors mediate efficient transduction of airway epithelial cells in mouse lungs compared to that of AAV2 vectors J. Virol. 75 2001 6615-6624
47. C.L. Halbert J.M. Allen A.D. Miller Efficient mouse airway transduction following recombination between AAV vectors carrying parts of a larger gene Nat. Biotechnol. 20 2002 697-701
48. A. Auricchio et al. Noninvasive gene transfer to the lung for systemic delivery of therapeutic proteins J. Clin. Invest. 110 2002 499-504
49. N. Kaludov K.E. Brown R.W. Walters J. Zabner J.A. Chiorini Adenoassociated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity J. Virol. 75 2001 6884-6893
50. F. Mingozzi et al. Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector J. Virol. 76 2002 10497-10502
51. R.W. Walters J.M. Pilewski J.A. Chiorini J. Zabner Secreted and transmembrane mucins inhibit gene transfer with AAV4 more efficiently than AAV5 J. Biol. Chem. 277 2002 23709-23713
52. D. Grimm M.A. Kay From virus evolution to vector revolution: Use of naturally occurring serotypes of adeno-associated virus (AAV) as novel vectors for human gene therapy Curr. Gene Ther. 3 2003 281-304
53. K. Qing C. Mah J. Hansen S. Zhou V. Dwarki A. Srivastava Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2 Nat. Med. 5 1999 71-77
54. J. Qiu K.E. Brown Integrin alphaVbeta5 is not involved in adeno-associated virus type 2 (AAV2) infection Virology 264 1999 436-440
55. C. Summerford R.J. Samulski Viral receptors and vector purification: New approaches for generating clinical-grade reagents Nat. Med. 5 1999 587-588
56. J. Qiu A. Handa M. Kirby K.E. Brown The interaction of heparin sulfate and adeno-associated virus 2 Virology 269 2000 137-147
57. G.P. Gao M.R. Alvira L. Wang R. Calcedo J. Johnston J.M. Wilson Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy Proc. Natl. Acad. Sci. USA 99 2002 11854-11859
58. B. Hauck W. Xiao Characterization of tissue tropism determinants of adenoassociated virus type 1 J. Virol. 77 2003 2768-2774
59. E.A. Jones J. Vergalla C.J. Steer P.R. Bradley-Moore J.M. Vierling Metabolism of intact and desialylated alpha 1-antitrypsin Clin. Sci. Mol. Med. 55 1978 139-148
60. R.A. Driskell J.F. Engelhardt Current status of gene therapy for inherited lung diseases Annu. Rev. Physiol. 65 2003 585-612
61. S. Ferrari U. Griesenbach D.M. Geddes E. Alton Immunological hurdles to lung gene therapy Clin. Exp. Immunol. 132 2003 1-8
62. J. Vadolas R. Williamson P.A. Ioannou Gene therapy for inherited lung disorders: An insight into pulmonary defence Pulm. Pharmacol. Ther. 15 2002 61-72
63. M.J. Welsh Gene transfer for cystic fibrosis J. Clin. Invest. 104 1999 1165-1166
64. R.C. Hubbard R.G. Crystal Strategies for aerosol therapy of alpha 1-antitrypsin deficiency by the aerosol route Lung 168 Suppl. 1990 565-578